Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 93,487,760
  • Shares Outstanding, K 1,672,710
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.09
  • Price/Sales 4.80
  • Price/Cash Flow 18.16
  • Price/Book 5.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.17 +1.31%
on 03/22/17
58.54 -4.53%
on 03/10/17
-0.55 (-0.97%)
since 02/24/17
3-Month
46.01 +21.47%
on 01/26/17
60.45 -7.54%
on 01/10/17
-3.72 (-6.24%)
since 12/23/16
52-Week
46.01 +21.47%
on 01/26/17
77.12 -27.53%
on 07/15/16
-6.63 (-10.60%)
since 03/24/16

Most Recent Stories

More News
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy

--Positive opinion based on overall survival benefit demonstrated in the Phase 3 CheckMate -141 trial

BMY : 55.89 (+0.22%)
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved

This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.

JNJ : 125.48 (-0.33%)
LLY : 84.18 (-0.28%)
NVS : 74.37 (-0.08%)
FLXN : 27.27 (+3.89%)
PFE : 34.00 (-0.85%)
SNY : 44.63 (+0.27%)
BMY : 55.89 (+0.22%)
Ontario Latest Province to Cover Cost of Immuno-Oncology Treatment OPDIVO® (nivolumab)

Eligible Ontario residents with difficult-to-treat advanced cancers can now access an innovative new treatment option without having to pay out-of-pocket

BMY : 55.89 (+0.22%)
Infinity Pharma Focuses on Cancer Drug: Competition Looms

We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.

CELG : 123.38 (+0.13%)
AZN : 31.31 (+0.03%)
INFI : 3.30 (+3.12%)
BMY : 55.89 (+0.22%)
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal

Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.

HSKA : 98.72 (+0.50%)
CTMX : 17.79 (+2.12%)
RTRX : 17.39 (-0.80%)
BMY : 55.89 (+0.22%)
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017

Glaxo carries a Zacks Rank #2 (Buy).

NVS : 74.37 (-0.08%)
UCBJF : 76.9300 (+8.46%)
GSK : 42.31 (unch)
BMY : 55.89 (+0.22%)
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody(TM) Therapeutics for the Treatment of Cancer and Other Diseases

--Includes up to eight additional targets in oncology and other therapeutic areas

CTMX : 17.79 (+2.12%)
BMY : 55.89 (+0.22%)
SmarTrend Watching for Potential Rebound in Shares of Bristol-Myers Squibb After 1.34% Loss

Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $56.11 to a high of $57.25. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of...

BMY : 55.89 (+0.22%)
Look for Shares of Bristol-Myers Squibb to Potentially Rebound after Yesterday's 1.34% Sell Off

Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $56.11 to a high of $57.25. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of...

BMY : 55.89 (+0.22%)
Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation

Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke...

PFE : 34.00 (-0.85%)
BMY : 55.89 (+0.22%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 56.52
1st Resistance Point 56.20
Last Price 55.89
1st Support Level 55.62
2nd Support Level 55.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.